Cystic fibrosis and Crohn's disease treated successfully with infliximab

April 19, 2010

A research team from Italy reported a case of a 23-year-old patient suffering from cystic fibrosis (CF) and Crohn's disease who was successfully treated with infliximab. This case report was thought to be one of the first regarding the use of biological therapy in patients with CF.

Cystic fibrosis (CF) is the most common life-threatening autosomal recessive disease in Caucasian children; it has an incidence of 1 case in every 2500 children born alive. CF involves an anomalous function of the exocrine glands, caused by a mutation of a gene ( transmembrane conductance regulator, CFTR) located on chromosome 7, which codes for a protein involved in ion transport through the cell membrane.

Pulmonary complications are the most common causes of mortality, but the presenting symptoms are very often linked to gastrointestinal and pancreatic biliary diseases. These are mainly caused by the unusual viscosity of the secretions in hollow organs and in the ducts of solid organs. Crohn's dis¬ease (CD) is a chronic which may be localized throughout the . The association between CD and CF is known; there are reports of a prevalence of CD in patients suffering from CF 17 times higher than in controls.

A research article to be published on April 21, 2010 in the addresses this question. A research team led by Professor Gian Luigi de' Angelis, reported the first case of a patient with CF and CD treated with .

After initiation of infliximab in this patient, there was an improvement of colonic lesions and general condition without any infective complication and particularly without any decline of lung function.

This report confirms the preliminary data regarding the possibility that airway inflammation in CF plays a crucial role in lung damage and that the inflammation is mediated by alpha. Therefore, the use of anti-tumor necrosis factor alpha antibody improved CD and did not generate any complications of lung function, perhaps promoting an anti-inflammatory effect both on colon and lung.

More information: Vincenzi F, Bizzarri B, Ghiselli A, de' Angelis N, Fornaroli F, de' Angelis GL. Cystic fibrosis and Crohn's disease: Successful treatment and long term remission with infliximab. World J Gastroenterol 2010; 16(15): 1924-1927. www.wjgnet.com/1007-9327/full/v16/i15/1924.htm

Related Stories

Recommended for you

Study opens new avenue in quest to develop tuberculosis vaccine

November 24, 2017
A team of scientists led by the University of Southampton has taken an important step forward in research efforts that could one day lead to an effective vaccine against the world's deadliest infectious disease.

Four simple tests could help GPs spot pneumonia and reduce unnecessary antibiotics

November 23, 2017
Testing for fever, high pulse rate, crackly breath sounds, and low oxygen levels could be key to helping GPs distinguish pneumonia from less serious infections, according to a large study published in the European Respiratory ...

New approach to tracking how deadly 'superbugs' travel could slow their spread

November 22, 2017
Killer bacteria - ones that have out-evolved our best antibiotics—may not go away anytime soon. But a new approach to tracking their spread could eventually give us a fighting chance to keep their death toll down.

Research points to diagnostic test for top cause of liver transplant in kids

November 22, 2017
Biliary atresia is the most common cause of liver transplants for children in the United States. Now researchers report in Science Translational Medicine finding a strong biomarker candidate that could be used for earlier ...

Alcohol consumption and metabolic factors act together to increase the risk of severe liver disease

November 22, 2017
A new study provides insights into the interaction between alcohol consumption and metabolic factors in predicting severe liver disease in the general population. The findings, which are published in Hepatology, indicate ...

Metabolites altered in chronic kidney disease

November 22, 2017
Chronic kidney disease (CKD) affects 1 in 7 people in the United States, according to the U.S. National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK). These individuals have a very high risk of cardiovascular ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.